CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 68 enrolled
Drug / intervention
anle138b +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04208152
NCT04208152Phase 1Completed
CompareCT.gov

A First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of anle138b in Healthy Male and Female Subjects

MODAG GmbH·interventional·Posted Dec 23, 2019·Updated Aug 6, 2020

In Brief

A Phase 1 clinical trial evaluating anle138b and Placebo for Healthy Volunteers. Completed, enrolled 68 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the safety, tolerability and blood levels of orally administered anle138b in healthy subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited Kingdom
CollaboratorsQuotient Sciences, Aptuit

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedDec 23, 2019
Enrollment StartDec 6, 2019
Primary CompletionAug 4, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.5 years ago

Interventions

anle138bdrug

capsule containing excipient and anle138b

Placebodrug

matching placebo capsule containing excipient